Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06874855
PHASE4

Lemborexant in Delayed Sleep Phase Syndrome

Sponsor: University of California, San Francisco

View on ClinicalTrials.gov

Summary

The purpose of the study is to evaluate whether Lemborexant is more effective than placebo in shortening sleep onset latency in patients with delayed sleep phase syndrome (both type 1 and type 2). This will be tracked using sleep logs as well as actigraphy. In this 2-year study, the investigators will examine if Lemborexant administered 5-10 mg nightly taken at desired bedtime (at least 2 hours prior to self-reported sleep onset habitual time) can improve the symptoms of Delayed Sleep Phase Syndrome.

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

15

Start Date

2023-03-13

Completion Date

2027-05-31

Last Updated

2025-04-24

Healthy Volunteers

Yes

Interventions

DRUG

Lemborexant

Lemborexant tablet administered orally once daily

DRUG

Placebo

Placebo to match Lemborexant tablet administered orally once daily

Locations (1)

University of California San Francisco

San Francisco, California, United States